Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
about
Computational neuropsychiatry - schizophrenia as a cognitive brain network disorderGroup II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsIn Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric DisordersNeurobiological Insights from mGlu Receptor Allosteric Modulation.Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsA selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.Major channels involved in neuropsychiatric disorders and therapeutic perspectivesHomozygous Deletion of Glutathione Peroxidase 1 and Aldehyde Dehydrogenase 1a1 Genes Is Not Associated with Schizophrenia-Like Behavior in MiceSelective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.The touchscreen operant platform for testing learning and memory in rats and miceTrans-synaptic zinc mobilization improves social interaction in two mouse models of autism through NMDAR activationElevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuseReviewing the ketamine model for schizophrenia.Microglial dysregulation in psychiatric diseaseMultiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunctionRedox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition.Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia.Holding multiple items in short term memory: a neural mechanism.Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviorsSex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia.Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.Maternal immune activation alters glutamic acid decarboxylase-67 expression in the brains of adult rat offspringState-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effectsRole for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in MiceGlutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Cortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases.Axonal Type III Nrg1 Controls Glutamate Synapse Formation and GluA2 Trafficking in Hippocampal-Accumbens ConnectionsImpact of glutamate levels on neuronal response and cognitive abilities in schizophrenia.A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine.Impact of structural aberrancy of polysialic acid and its synthetic enzyme ST8SIA2 in schizophrenia.Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.Animal models for predicting the efficacy and side effects of antipsychotic drugs.Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment
P2860
Q22241226-4AFCBE80-215F-4424-BB09-1A49966245D6Q26744729-46A6B2A9-2BBF-41B3-B397-210D9180EF04Q26769948-A6B60BCC-AAE5-46A3-B0C9-E144F177166FQ26773431-7FB119F1-7363-465C-95A9-7A015559AC7AQ27305419-622D45E7-2120-4EAB-BB31-6FCF30CAEB50Q28082048-8F4420ED-74A5-4B91-8BB7-896215B715F9Q28290639-E1E1B758-7B1D-41F7-9B7A-84177F2DB492Q28395280-8DA428D2-1BD6-43F9-AA32-422A3CAFD6A9Q30406145-DE69F06C-1430-4D0D-8BED-8CF0E571474AQ30437188-E1B22308-118D-4A42-9923-095CF4EF43E3Q30570928-4E3F1EB0-60A7-437C-9ECD-DEBCA853FEC9Q30655543-0598564D-98E4-4A86-B98E-420B56B5D2C1Q34018212-D7EA47B6-FAC4-4BF4-B7F1-9C58C4C17267Q34046060-ED691A38-F2C4-474B-913E-C3E3313E76E1Q34345744-3D0DDF20-EF7A-410E-9C8D-4D9D38B1680BQ34348224-4C6954F7-D5C3-424B-AC66-7D51EEC08068Q34428194-AB7E7EB2-13C6-42C3-B55C-E1271E81E912Q34484352-AA8EF756-94DC-483E-8456-7DF9DA0ED4CDQ34534903-8FE0CE4D-024E-4952-93D9-A7FACD40A67FQ34684019-74FF7747-5507-4D2E-88CF-ECA09A2B60BCQ35132662-997412BE-6DFF-435F-8F3E-BAE4FF0EC9F4Q35915861-9C373E7D-4383-4868-8C54-53A0E40392D6Q36096029-F4D879DC-24B8-4AE1-8836-4062E3CE5EB4Q36246819-190D46E0-CD04-41AB-B684-7582AE67D8D8Q36715847-0A5F5D21-7349-4982-BAA3-7D6D22F5D116Q36732752-C1FD92FD-313A-4110-99FD-15D655148B83Q36794968-E06FF406-12A6-41A4-A15C-A75C031D38EFQ37121338-A95CAE29-D588-44D6-B0C8-8589FA4D2BEFQ37561567-3D9A8234-E984-4B2A-853E-300E5B8F5857Q37670717-B26A5EDF-97EB-41D3-9B04-619D0E79A4A5Q37707322-A914EA91-7EC0-4ED9-90AC-06C91B92DE8FQ37707718-22435CAC-8032-41EF-8A0B-572AE4058D31Q38082838-F14FE3BC-6CCD-4520-B2D6-BC1122559028Q38106974-BCD5A309-DD89-433B-9777-B27E5CB8D958Q38133757-51C4D05F-E7FA-4B15-83B6-F69DDAA897E8Q38149953-C2A0BC39-5536-4431-937C-C482FFA44D3FQ38154625-ADE2B8D5-D21C-46C8-88CF-5C38D037A4E0Q38165756-A0D3E4F0-BDC5-401C-BC30-E5E5DC4D83B5Q38207021-81964BAE-66B7-4258-AE4F-61F56FD072CBQ38213709-23B68E4A-64A3-4FDF-A4EC-7F4559458686
P2860
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@ast
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@en
type
label
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@ast
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@en
prefLabel
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@ast
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@en
P2093
P2860
P1476
Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.
@en
P2093
Darrick Balu
Glenn Konopaske
Joseph T Coyle
Michael Benneyworth
P2860
P304
P356
10.1007/978-3-642-25758-2_10
P577
2012-01-01T00:00:00Z